Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.47 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.43 |
| ▸ | PDE4A | P27815 | 6/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12180578 | 0.89 | KAT2B (0.56) | KAT2BBAZ2BALDH1A1GLASLC6A2 | |
| SCHEMBL18419663 | 0.85 | ALDH1A1 (0.50) | ALDH1A1GLASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL2226298 | 0.84 | KAT2B (0.40) | KAT2BBAZ2BPDE4DPDE4APDE4B | |
| SCHEMBL15696504 | 0.81 | PDE4D (0.43) | SLC6A2SLC6A4PDE4DPDE4APDE4B | |
| SCHEMBL14877634 | 0.81 | PDE4D (0.43) | SLC6A2SLC6A4PDE4DPDE4APDE4B | |
| SCHEMBL15468356 | 0.81 | PDE4D (0.43) | SLC6A2SLC6A4PDE4DPDE4APDE4B | |
| SCHEMBL24498739 | 0.81 | SYK (0.46) | PDE4DPDE4APDE4BPDE4CSYK | |
| SCHEMBL1928290 | 0.79 | KAT2B (0.43) | KAT2BBAZ2BPDE4DPDE4APDE4B | |
| SCHEMBL3799931 | 0.79 | KAT2B (0.43) | KAT2BBAZ2BALDH1A1PDE4DPDE4A | |
| SCHEMBL3801070 | 0.79 | KAT2B (0.43) | KAT2BBAZ2BALDH1A1PDE4DPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1903045-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-03-26 | — | — | EP | disclosed |
| WO-2001072751-A1 | PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS | KNOLL GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MC2R, CRHR1, AVPR2 | KAT2B 2804/4885BAZ2B 1012/4885ALDH1A1 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.